RENO, Nev., Sept. 30, 2011 /PRNewswire/ -- Lifeline
Biotechnologies, Inc. (Pink Sheets: LLBO) announced today that the
Company continues efforts to reestablish DTC services.
Jim Holmes, Lifeline's CEO said
"While our efforts have continued to reestablish DTC's services to
the Company we have not been successful. We now are
considering alternatives should the circumstances not change.
The value of Lifeline is not reflected in the current lack of
liquidity (low per share market price and low daily volume of
shares traded). Lifeline's investment in First Warning
Systems has not diminished; in fact, First Warning's value has
appreciated as established milestones have been achieved. Our
focus in First Warning is preparation for the final round of
clinical trials estimated to commence in the latter half of 2012.
At this time, our best estimate for trial completion is late
2013. The trails must be successfully completed before our FDA
medical device marketing application is submitted in the U.S."
Safe Harbor: This release includes forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 27E of the Securities Act of 1934. Statements
contained in this release that are not historical facts may be
deemed to be forward-looking statements. Investors are cautioned
that forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected
or suggested herein due to certain risks and uncertainties
including, without limitation, the ability to obtain financing,
successful development of the Company's product or market
acceptance of the product and regulatory and shareholder approval
for anticipated actions.
CONTACT: Lifeline Biotechnologies, Inc.
Jim Holmes, 775-326-9614
Email: Jholmes@lbti.com website:
www.lbti.com
SOURCE Lifeline Biotechnologies, Inc.